BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Products » [SALE] CAR-T Funding Brief – Financing Rounds, Acquisitions, & IPOs
Sale!
CAR-T Funding Brief

[SALE] CAR-T Funding Brief – Financing Rounds, Acquisitions, & IPOs

Category: Cell Therapy Tag: CAR-T
  • Description

Description

CAR-T funding is on the rise. At first the trend was subtle, but the tide has swelled as CAR-T therapies like Kymriah, Yescarta, Tecartus, Breyanzi, and Abecma have reached the marketplace and created a CAR-T funding craze. CAR-T start-ups have been richly funded by investors eager to get into this trending area of regenerative medicine.

Discover class-defining bioproduction tools.

In total, financing rounds by CAR-T companies are approaching a total value of $4 billion, while CAR-T industry partnerships contribute another $2 billion.

M&A activity has been even more aggressive, with Celgene snagging Juno Therapeutics for $9 billion in 2018 and Bristol-Myers Squibb (BMS) acquiring Celgene for $74B by 2019. Gilead’s acquisition of Kite Pharma for $11.9 billion also made waves, as have other M&A transactions such as Astellas Pharma’s acquisition of Xyphos Biosciences and its CAR-T technology for $665 million.

In aggregate, there has been nearly $100 billion of market capitalization from CAR-T companies within recent years. Ranging from small start-ups to billion dollar companies, CAR-T companies are proliferating in all healthcare markets worldwide.

CAR-T Market Overview

To track these industry events, BioInformant has released a 56-page CAR-T market brief.

It summarizes all types of investments flowing into CAR-T companies worldwide, including financing rounds, IPOs, M&A transactions, co-development agreements, and strategic partnerships.

It also profiles 100+ market competitors that are involved with developing CAR-T technologies.

It features the following information for the CAR-T industry:

  • Financing Rounds
  • IPOs
  • Asset Agreements
  • Strategic Partnerships
  • M&A Transactions
  • Companies Profiles for 100+ CAR-T Competitors

Use it to:

  1. Quantify CAR-T industry investments
  2. Identify well-capitalized companies
  3. Scout potential partnerships and alliances
  4. Understand partnerships and co-development programs for CAR-T technologies
  5. Identify M&A activity within the CAR-T industry

Summary

While this research was originally compiled for our own internal use, more and more clients have been requesting access to it. With the recent frenzy of CAR-T funding, it is time for you to take advantage of this rapidly expanding marketplace too.

Would you benefit from knowing all CAR-T industry investments and transactions worldwide?

If so, you’re down to your final hours to access this 56-page report for only $49 (75% off). When you claim it below, your PDF file will be available for immediate download with unlimited access and printing rights allowed.

Of course, your investment is backed by BioInformant’s 60-Day Money Back Guarantee.

$197 $49

Related products

  • Sale! Database of CAR-T Cell Therapy Companies (2018) - BioInformant

    [SALE] Global Database of CAR-T Cell Therapy Companies, 2022

    $124 – $297
    Select options
  • Cell and Gene Therapy Manufacturing

    The Market for Cell and Gene Therapy Manufacturing – Rise of CMOs & CDMOs

    $1,297 – $1,997
    Select options
  • Sale! Global CAR-T Cell Therapy Market – Market Size, Forecasts, Trials & Trends

    [NEW] Global CAR-T Cell Therapy Market – Market Size, Forecasts, Trials & Trends, 2022

    $3,349 – $4,597
    Select options
  • Sale! Cell and Gene Therapy CMOs

    [SALE] Global Database of Cell and Gene Therapy CMOs and CDMOs, 2022

    $124 – $249
    Select options

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.